Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R-Reference-Cited by-同舟云学术

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

Published:2014-04-10 Issue:15 Volume:123 Page:2333-2342
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Della Porta Matteo G.¹²,Alessandrino Emilio Paolo¹,Bacigalupo Andrea³,van Lint Maria Teresa³,Malcovati Luca¹⁴,Pascutto Cristiana¹,Falda Michele⁵,Bernardi Massimo⁶,Onida Francesco⁷,Guidi Stefano⁸,Iori Anna Paola⁹,Cerretti Raffaella¹⁰,Marenco Paola¹¹,Pioltelli Pietro¹²,Angelucci Emanuele¹³,Oneto Rosi³,Ripamonti Francesco¹,Bernasconi Paolo¹⁴,Bosi Alberto⁸,Cazzola Mario¹⁴,Rambaldi Alessandro¹⁴

Affiliation:

1. Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;

2. Department of Internal Medicine, University of Pavia, Pavia, Italy;

3. Department of Hematology, San Martino Hospital, Genova, Italy;

4. Department of Molecular Medicine, University of Pavia, Pavia, Italy;

5. Department of Hematology, San Giovanni Battista Hospital, Turin, Italy;

6. Hematology and Bone Marrow Transplant Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy;

7. Hematology and Bone Marrow Transplantation Center, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico and University of Milan, Milan, Italy;

8. Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;

9. Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;

10. Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Policlinico Tor Vergata, Rome, Italy;

11. Department of Hematology Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy;

12. Division of Hematology and Transplant Unit, Ospedale San Gerardo, Monza, Italy;

13. Hematology and Bone Marrow Transplantation Unit, Ospedale Oncologico di Riferimento Regionale Armando Businco, Cagliari, Italy; and

14. Hematology and Bone Marrow Transplant Units of Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

Abstract

Key Points Disease relapse is a common cause of failure of allogeneic hematopoietic stem cell transplantation in patients with advanced MDS. High IPSS-R prognostic risk category and monosomal karyotype are independent predictors of relapse after allogeneic transplantation in MDS.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/15/2333/1375542/2333.pdf

Reference38 articles.

1. The genetic basis of myelodysplasia and its clinical relevance.;Cazzola;Blood,2013

2. Clinical effect of point mutations in myelodysplastic syndromes.;Bejar;N Engl J Med,2011

3. Frequent pathway mutations of splicing machinery in myelodysplasia.;Yoshida;Nature,2011

4. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.;Papaemmanuil;N Engl J Med,2011

5. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.;Malcovati;Blood,2011

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current challenges in conditioning regimens for MDS transplantation;Blood Reviews;2024-09

2. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes;Journal of Clinical Oncology;2024-08-20

3. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?;Blood;2024-07-25

4. Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study;Leukemia Research;2024-07

5. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee;Blood;2024-05-30